Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Table 2 Summary of adverse events

	Overall (N = 8)
AE Categories	n (%)	Events
Any AE	8 (100.0)	71
Any SAE	1 (12.5)	1
Fatal TEAEs	0 (0.0)	0
TEAEs or TESAEs resulting in drug discontinuation	0 (0.0)	0
TEAEs or TESAEs resulting in study discontinuation	0 (0.0)	0
Meningococcal infections	0 (0.0)	0
Treatment-related AEs (all considered possibly-related)	2 (25.0)	3

AE adverse event, SAE serious adverse event, TEAE treatment-emergent adverse event, TESAE treatment-emergent serious adverse event

ISSN: 1471-2369